Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for The Cancer Drugs Granted Conditional Approval in China
Journal articles
Luo, X; Du, X; Huang, L; Guo, Q; Lv, X; Wang, M; Liu, H; Zhou, Y; Xue, X; Li, Z; Liu, J; Chow, S-C; Yang, Y
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Luo, X., Du, X., Huang, L., Guo, Q., Lv, X., Wang, M., … Yang, Y. (n.d.). Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for The Cancer Drugs Granted Conditional Approval in China.
Luo, Xingxian, Xin Du, Lin Huang, Qixiang Guo, Xufeng Lv, Miao Wang, Haopeng Liu, et al. “Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for The Cancer Drugs Granted Conditional Approval in China,” n.d.
Luo X, Du X, Huang L, Guo Q, Lv X, Wang M, et al. Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for The Cancer Drugs Granted Conditional Approval in China.
Luo X, Du X, Huang L, Guo Q, Lv X, Wang M, Liu H, Zhou Y, Xue X, Li Z, Liu J, Chow S-C, Yang Y. Assessment of Clinical Trial Evidence and Surrogate Endpoints Strength for The Cancer Drugs Granted Conditional Approval in China.